Key Takeaways
- • Arlington Capital Partners-backed AVS Bio has acquired Biorbyt, a Cambridge-based bioreagent supplier founded in 2011, in an add-on acquisition to expand its life science research portfolio.
- • Biorbyt operates a catalog exceeding 1 million SKUs encompassing bio-reagents, antibodies, proteins, and other biomaterials used in life science research, positioning the combined entity for broader market reach.
- • The transaction represents a strategic consolidation within the life science reagent supply sector, leveraging Arlington's portfolio company infrastructure to integrate complementary product offerings and customer bases.
Summary
AVS Bio, backed by private equity firm Arlington Capital Partners, has completed the acquisition of Biorbyt, a specialized supplier of bioreagents and biomaterials based in Cambridge, UK. Classified as an add-on deal, the transaction expands AVS Bio's capabilities within the life science research supply chain.
Biorbyt, established in 2011, has built a substantial presence in the bioreagent market through a diversified product catalog exceeding 1 million SKUs. The company supplies critical research materials including antibodies, proteins, and other biomaterials to the global life science community, serving both academic and commercial research institutions.
The acquisition aligns with a broader consolidation strategy within the life science research tools sector, where larger platforms are integrating specialized suppliers to create comprehensive product portfolios and enhance distribution efficiency. By adding Biorbyt's established customer relationships and extensive catalog to AVS Bio's existing operations, Arlington Capital Partners continues to build scaled platforms within the life sciences ecosystem.
The deal underscores ongoing activity in the alternative investment sector's life science services vertical, where portfolio companies pursue targeted add-on acquisitions to drive organic growth and operational synergies within their platforms.
Biorbyt, established in 2011, has built a substantial presence in the bioreagent market through a diversified product catalog exceeding 1 million SKUs. The company supplies critical research materials including antibodies, proteins, and other biomaterials to the global life science community, serving both academic and commercial research institutions.
The acquisition aligns with a broader consolidation strategy within the life science research tools sector, where larger platforms are integrating specialized suppliers to create comprehensive product portfolios and enhance distribution efficiency. By adding Biorbyt's established customer relationships and extensive catalog to AVS Bio's existing operations, Arlington Capital Partners continues to build scaled platforms within the life sciences ecosystem.
The deal underscores ongoing activity in the alternative investment sector's life science services vertical, where portfolio companies pursue targeted add-on acquisitions to drive organic growth and operational synergies within their platforms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.